DKK1 and hepatocellular carcinoma: This phenomenon can raise the necessities for further in-vivo studies which can provide the evidences that simultaneous suppression of VEGFR2 by blocking DKK-1 and sorafenib treatment can have synergistic effects on HCC treatment.